Henry Schein, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSIC research report →
Range $85 – $110
Price Chart
About the company
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities.
- CEO
- Frederick Lowery
- IPO
- 1995
- Employees
- 25,000
- HQ
- Melville, NY, US
Get TickerSpark's AI analysis on HSIC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.23B
- P/E
- 22.48
- Fwd P/E
- 15.14
- PEG
- 1.43
- P/S
- 0.67
- P/B
- 2.92
- EV/EBITDA
- 11.80
- Div Yield
- 0.00%
- Gross Margin
- 30.57%
- Op Margin
- 5.70%
- Net Margin
- 3.07%
- ROE
- 13.13%
- ROIC
- 6.50%
Latest fiscal year · YoY change
- Revenue
- $13.18B+4.0%
- Gross Profit
- $3.84B+2.0%
- Op Income
- $758.00M
- Net Income
- $398.00M+2.1%
- EPS
- $3.29+7.2%
- OCF Growth
- -16.0%
- FCF Growth
- -13.3%
- 52W High
- $92.18
- 52W Low
- $68.70
- 50D MA
- $85.60
- 200D MA
- $81.72
- Beta
- 0.86
- RSI (14)
- 45
- Avg Volume
- 1.32M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Henry Schein said Q3 showed share gains and margin expansion, and raised full-year non-GAAP EPS guidance on tariff refunds plus ongoing value-creation benefits.· November 3, 2026
- U.S. dental merchandise sales rose 8.6% year over year, with 7% local-currency internal growth driven mainly by volume rather than price.
- Non-GAAP operating margin expanded 20 basis points and adjusted non-GAAP EPS increased 19.1% to $1.37, excluding tariff-refund and prior-year remeasurement effects.
- Management raised 2026 non-GAAP EPS guidance to $5.50-$5.56 from $5.29-$5.39; total sales growth guidance stayed at 4.5%-5.5%.
- The company repurchased $125 million of stock in the quarter and $450 million year to date, while still targeting more than $200 million of operating income improvement and a $125 million run rate by end-2026.
- Growth was strong in cloud-based technology, home solutions, and implants, while Brazil and point-of-care diagnostics remained headwinds.
Henry Schein reported Q3 global sales of $3.5 billion, up 4.0% year over year, with 3.1% local-currency internal growth, 0.2% from FX, and 0.7% from acquisitions. GAAP net income was $119 million, or $1.06 per diluted share, versus $101 million, or $0.84, a year ago; non-GAAP net income was $175 million, or $1.56 per diluted share, versus $167 million, or $1.38. Non-GAAP operating margin was 8.03%, up 20 basis points; GAAP operating margin was 5.57%, up 69 basis points; adjusted EBITDA was $295 million versus $321 million in the prior year period as stated in the call. U.S. dental merchandise sales grew 8.6%, U.S. dental equipment sales grew 1.6%, U.S. medical sales grew 1.0%, and global technology sales grew 5.2%. Full-year 2026 guidance was raised: total sales growth remains 4.5%-5.5%, non-GAAP diluted EPS is now $5.50-$5.56, and adjusted EBITDA is expected to grow in the high single digits. Management said the raise reflects tariff refunds, targeted fourth-quarter growth investments, and improved underlying business performance; it also said no GAAP guidance is being provided because restructuring costs cannot be estimated without unreasonable effort.
Frederick Lowery said the quarter validated Henry Schein’s strategy: the company is gaining share, expanding margins, and converting revenue growth into stronger earnings. He repeatedly emphasized that U.S. dental growth was mostly volume-driven, especially in private practices and emerging DSOs, and tied that to company-owned brands, exclusive products, and better commercial execution. He also framed the fourth-quarter spending as limited and selective, aimed at accelerating growth now and building momentum into 2027, while maintaining a disciplined approach to capital allocation.
Ronald South highlighted the quarter’s financial bridge: $3.5 billion in sales, $119 million in GAAP net income, $175 million in non-GAAP net income, and $1.56 non-GAAP EPS, with the EPS results helped by a $0.19 per share tariff-refund benefit. He said the tariff refund benefit was about $28 million flowing through cost of goods sold, with roughly $2 million of offsetting OpEx and about $1 million of interest income. South also reiterated more than $200 million of operating income improvement, including a $125 million run rate by the end of 2026, noted $125 million of share repurchases in the quarter and $330 million still authorized, and said operating cash flow was $161 million and is expected to exceed net income for the full year.
Analysts pressed management on whether U.S. dental consumables growth was driven by volume or price, and management said it was primarily volume, with share gains in private practices and emerging DSOs, plus growth in company-owned and exclusive products. Multiple questions focused on the $0.19 tariff-refund benefit and whether it should be treated as recurring; management said it is difficult to repeat period to period, but they chose not to adjust it out for non-GAAP because it is a refund of prior costs and they will isolate it when relevant. Analysts also asked about the path to double-digit EPS growth and 2027 math; management said it remains confident in double-digit earnings growth over time, but will incorporate tariffs and other items when it provides 2027 guidance.
The call showed broad-based momentum in dental, especially U.S. consumables, where management said growth is coming from volume, share gains, and deeper customer penetration rather than just pricing. Technology, implants, and home solutions were also growing, and management said its value-creation program is already contributing to margin expansion and earnings growth. Leadership sounded confident that targeted investments and simplification initiatives can extend the momentum into 2027.
Management acknowledged pressure in discretionary procedures, softer point-of-care diagnostics, and weaker flu and COVID vaccine sales, and said Brazil remains a headwind in specialty products. The fourth-quarter EPS comparison is also complicated by the absence of prior-year remeasurement gains, and management emphasized that the tariff-refund benefit is hard to repeat. In addition, some of the raised guidance reflects targeted investment and one-time tariff-related benefits rather than purely recurring operating improvement.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.1%
- Shares Outstanding
- 110.54M
- Float Shares
- 90.80M
of shares held by institutions
579 13F filers
Congressional trading
Senate and House stock disclosures for HSIC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Sell | Jun 18, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 9, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Apr 1, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | Apr 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 31, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Aug 26, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 17, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 17, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 14, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 1, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Nov 14, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 15.65M | 0 |
| Vanguard Group Inc | 11.59M | ▼ 412.58K |
| Fmr LLC | 7.72M | ▲ 162.65K |
| Blackrock, Inc. | 7.06M | ▲ 32.35K |
| Vanguard Capital Management LLC | 6.25M | ▼ 94.53K |
| Artisan Partners Limited Partnership | 5.51M | ▼ 961.90K |
| State Street Corp | 4.30M | ▼ 3.17K |
| Vanguard Portfolio Management LLC | 4.07M | ▼ 64.27K |
| Jpmorgan Chase & Co | 3.57M | ▼ 772.18K |
| Dimensional Fund Advisors LP | 3.52M | ▲ 129.20K |
| Southpoint Capital Advisors LP | 3.30M | ▲ 100.00K |
| Invesco Ltd. | 3.02M | ▼ 126.41K |
Held by 888 ETFs
Biggest fund positions in HSIC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | Caprais Emmanuel | other | 0 |
| Sep 8, 26 | Albertini Andrea | other | 603 |
| Sep 8, 26 | Albertini Andrea | sell | 3,984 |
| Jun 12, 26 | DANIEL WILLIAM K | other | 2,215 |
| May 21, 26 | Murphy Kelly Ann | other | 0 |
| May 21, 26 | Murphy Kelly Ann | other | 0 |
| May 21, 26 | Murphy Kelly Ann | other | 0 |
| May 21, 26 | Murphy Kelly Ann | other | 0 |
| May 26, 26 | BERGMAN STANLEY M | other | 50 |
| May 21, 26 | BERGMAN STANLEY M | other | 50 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HSIC coverage
Recent articles, reports, and earnings notes.

SmileDirectClub, IPO: What to Know Before It Lists
SmileDirectClub, Inc. is expected to list on NASDAQ on 2026-11-18, but the price range has not been disclosed. The company is a direct-to-consumer oral care and medtech platform built around teledentistry and clear aligners. Watch for how investors weigh fast revenue growth against regulatory risk, litigation, and leverage.

Inside the vVARDIS Holding AG IPO: Growth, Risks, and Verdict
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.

What to Watch as vVARDIS Holding AG Prices Its NYSE IPO
vVARDIS Holding AG is expected to list on the NYSE on 2026-11-13 under the symbol VVVV, with shares priced at $21.00 to $24.00. The Swiss dental company is pitching a first-in-category treatment for early-stage cavities, but investors will be watching how much of the story is already priced in. The bull case is rapid revenue growth and a large untapped dental market; the bear case is regulatory, supply-chain, and founder-overhang risk.
Want a deeper read on HSIC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Henry Schein, Inc. (HSIC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Henry Schein Updates Presentation of Non-GAAP Financial Measures
businesswire.com · Nov 16
CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration
businesswire.com · Nov 10
Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com · Nov 5
Henry Schein (HSIC) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Nov 5
HSIC vs. MMSI: Which Stock Should Value Investors Buy Now?
zacks.com · Nov 5
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
zacks.com · Nov 5
Is Henry Schein (HSIC) Stock Undervalued Right Now?
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.